Table A7.
Histology if Surgery for Residual Masses in Patients With Nonseminoma
| Worst Histology of Resected Specimens | Treatment |
Total (N = 235) |
||||
|---|---|---|---|---|---|---|
| BEP (n = 116) |
T-BEP (n = 119) |
|||||
| No. of Patients | % | No. of Patients | % | No. of Patients | % | |
| Normal | 6 | 5.2 | 3 | 2.5 | 9 | 3.8 |
| Necrosis/fibrosis | 39 | 33.6 | 41 | 34.5 | 80 | 34.0 |
| Diff.teratoma | 26 | 22.4 | 39 | 32.8 | 65 | 27.7 |
| Viable mal.teratoma | 15 | 12.9 | 9 | 7.6 | 24 | 10.2 |
| Non–germ cell cancer | 2 | 1.7 | 0 | 0.0 | 2 | 0.9 |
| Other | 6 | 5.2 | 7 | 5.9 | 13 | 5.5 |
| Missing | 22 | 19.0 | 20 | 16.8 | 42 | 17.9 |
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; Diff, differentiated; Mal, malignant; T-BEP, paclitaxel–bleomycin, etoposide, and cisplatin.